id: NEW:pharmacotherapy_treatment_options_to_NEW:ptsd_sud_health_outcomes
name: Pharmacotherapy Treatment Options for PTSD-SUD â†’ PTSD-SUD Health Outcomes
from_node:
  node_id: NEW:pharmacotherapy_treatment_options
  node_name: Pharmacotherapy Treatment Options for PTSD-SUD
to_node:
  node_id: NEW:ptsd_sud_health_outcomes
  node_name: PTSD-SUD Health Outcomes
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Expanding pharmacological treatment options provides alternatives when psychosocial therapy
  barriers exist'
- 'Step 2: Pharmacotherapy can be delivered through primary care and general medical settings, improving
  geographic access'
- 'Step 3: Medication-based treatment may reduce time and travel burden compared to intensive psychotherapy'
- 'Step 4: Combined pharmacological and psychosocial approaches may improve outcomes beyond either alone'
evidence:
  quality_rating: A
  n_studies: 29
  primary_citation: 'Megan Swannell et al. 2025. "Pharmacological treatments for co-occurring PTSD and
    substance use disorders: A systematic review.." https://doi.org/10.1016/j.josat.2024.209601'
  supporting_citations:
  - 16 pharmacotherapies examined across included studies
  - Review includes RCTs and observational study designs
  - Review calls for consistent dosing and outcome measures for future meta-analysis
  doi: 10.1016/j.josat.2024.209601
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The systematic review identified 16 pharmacotherapies across 29 studies as potential treatment
  options to enhance outcomes for co-occurring PTSD and SUD, addressing barriers present with psychosocial
  therapy-only approaches.
spatial_variation:
  varies_by_geography: true
  variation_notes: Pharmacotherapy access may vary by prescriber availability, insurance coverage, and
    formulary restrictions across geographic regions
moderators:
- name: study_population
  direction: strengthens
  strength: moderate
  description: Evidence base concentrated in veteran populations who may have different treatment access
    and response patterns
structural_competency:
  equity_implications: 'This mechanism addresses healthcare system structure as a determinant of outcomes.
    By identifying pharmacological options, the review aims to reduce structural barriers (geography,
    time, specialist availability) that limit access to psychosocial therapies. However, the review notes
    limitations: inconsistent dosing, populations, and outcome measures across studies prevented meta-analysis,
    indicating the need for more standardized research infrastructure.'
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.736120'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
